Clinical Trial Update: Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial update on the efficacy of the BAd regimen in relapsed and refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BAd regimen
• Bendamustine (Bendamustine)

Snippet

Sponsor: Liao Aijun | Conditions: Bendamustine, Multiple Myeloma | Phase 3 | Status: UNKNOWN